Free tool
FAERS Monitor: Jakafi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202192 or its brand name (Jakafi, Ruxolitinib Phosphate). Reports on generic versions are filed under their own applications.
Reports
68,626
Serious
34,968
51% of reports
Hospitalization
13,793
Death reported
9,975
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use14,354
- death6,468
- fatigue6,200
- anaemia3,160
- haemoglobin decreased2,999
- platelet count decreased2,726
- diarrhoea2,709
- asthenia2,567
- dizziness2,518
- product dose omission issue2,480
- headache2,393
- pneumonia2,193
- nausea2,171
- product availability issue2,022
- weight increased2,000
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 483 |
| 2013 | 839 |
| 2014 | 2,779 |
| 2015 | 2,509 |
| 2016 | 4,603 |
| 2017 | 4,335 |
| 2018 | 5,006 |
| 2019 | 5,210 |
| 2020 | 6,094 |
| 2021 | 6,475 |
| 2022 | 6,434 |
| 2023 | 6,566 |
| 2024 | 6,205 |
| 2025 | 6,136 |
| 2026 | 4,952 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,985,533 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product availability issueSignal | 2,022 | 29.8 | 28.5 | 51,260 |
| haemoglobin decreasedSignal | 2,999 | 9.2 | 8.9 | 21,348 |
| platelet count decreasedSignal | 2,726 | 8.0 | 7.7 | 16,393 |
| anaemiaSignal | 3,160 | 5.1 | 5.0 | 10,474 |
| off label useSignal | 14,354 | 5.1 | 5.0 | 48,429 |
| weight increasedSignal | 2,000 | 2.8 | 2.6 | 2,234 |
| product dose omission issueSignal | 2,480 | 2.6 | 2.5 | 2,450 |
| fatigueSignal | 6,200 | 2.5 | 2.4 | 5,492 |
| deathSignal | 6,468 | 2.3 | 2.3 | 4,976 |
| astheniaSignal | 2,567 | 2.1 | 2.0 | 1,494 |
| pneumoniaSignal | 2,193 | 2.1 | 2.0 | 1,245 |
| dizziness | 2,518 | 1.6 | 1.5 | 500 |
| diarrhoea | 2,709 | 1.3 | 1.2 | 178 |
| headache | 2,393 | 1.2 | 1.1 | 61 |
| nausea | 2,171 | 0.8 | 0.8 | 68 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.